Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) - Results of a US national survey
| Autor: | Robert C. Block, Dean G. Karalis, Nathan D. Wong, Amy L. Peterson, Matthew Bang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Heterozygote Time Factors Adolescent Endocrinology Diabetes and Metabolism Low density lipoprotein cholesterol Primary care Disease Familial hypercholesterolemia Drug Prescriptions Physicians Primary Care Hyperlipoproteinemia Type II Young Adult Cardiologists Surveys and Questionnaires Internal Medicine medicine Humans Referral and Consultation Nutrition and Dietetics business.industry PCSK9 PCSK9 Inhibitors Cholesterol LDL Awareness medicine.disease United States Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | Journal of clinical lipidology. 15(5) |
| ISSN: | 1933-2874 |
| Popis: | HeFH is a common inherited disorder that leads to markedly elevated LDL-cholesterol from birth and premature cardiovascular disease. HeFH is frequently underdiagnosed and undertreated.To compare how well primary care physicians and cardiologists recognize and treat HeFH.The National Lipid Association surveyed 500 primary care physicians and 500 cardiologists in the US who have patients with baseline LDL-cholesterol ≥ 190 mg/dL. The survey was conducted between August 29 and September 30, 2019.For a hypothetical case of HeFH, 57% of cardiologists versus 43% of primary care physicians made the correct diagnosis (P0.001). Among respondents, 21% of cardiologists versus 29% of primary care physicians have never made a diagnosis of HeFH in a patient with an LDL-cholesterol ≥ 190 mg/dL (P0.004). Only 7% of cardiologists versus 5% of primary care physicians would refer to a lipid specialist (P=0.05). For additional LDL-cholesterol lowering after statins, 58% of cardiologists versus 48% of primary care physicians would prescribe a PCSK9 inhibitor (P=0.004); however, 30% of cardiologists versus 53% of primary care physicians have never prescribed a PSCK9 inhibitor in an HeFH patient (P0.001).Although cardiologists compared to primary care physicians are somewhat more likely to recognize and treat HeFH patients according to guidelines, both physician specialties do not adequately recognize or treat HeFH. There is a need for more education and training in recognizing and treating HeFH, greater access to lipid specialists, and fewer barriers for PCSK9 inhibitor use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect